Michael Hallek to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Michael Hallek has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
3.549
-
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 05; 33(5):1161-1172.
Score: 0.359
-
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
Score: 0.350
-
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar; 14(6):499-513.
Score: 0.339
-
Chronic lymphocytic leukaemia. Lancet. 2018 04 14; 391(10129):1524-1537.
Score: 0.339
-
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 Sep; 92(9):946-965.
Score: 0.328
-
Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705.
Score: 0.318
-
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14; 127(2):208-15.
Score: 0.288
-
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015; 11(1):51-9.
Score: 0.273
-
COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020 08; 34(8):2225-2229.
Score: 0.100
-
Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019 11; 104(11):2144-2154.
Score: 0.095
-
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
Score: 0.092
-
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018 12; 183(5):727-735.
Score: 0.089
-
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 06; 60(6):1438-1446.
Score: 0.089
-
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk Lymphoma. 2019 03; 60(3):649-657.
Score: 0.088
-
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia. 2017 10; 31(10):2251-2253.
Score: 0.081
-
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Des Devel Ther. 2017; 11:295-304.
Score: 0.079
-
Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 09; 367(6):520-31.
Score: 0.058
-
[Elderly patients in clinical trials: new fitness-adapted concepts]. Internist (Berl). 2007 Nov; 48(11):1232-7.
Score: 0.041
-
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol. 2007 Jan; 136(1):63-72.
Score: 0.039
-
Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med. 2018 12; 58:7-13.
Score: 0.022
-
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018 10; 37(42):5682-5693.
Score: 0.022
-
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. Leuk Lymphoma. 2018 07; 59(7):1614-1623.
Score: 0.021
-
Targeting of B-cell receptor signalling in B-cell malignancies. J Intern Med. 2017 11; 282(5):415-428.
Score: 0.020
-
A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer. 2017 Feb 28; 116(5):600-608.
Score: 0.020